Sanofi SA vs Merck &: why the prices moved differently

• ▲

  New drug sales surge 48.3% Sanofi's new and acquired drugs, like Altuviiio and Sarclisa, grew sales 48.3% to €1.3 billion in Q2. This shows the company is building new revenue sources beyond Dupixent, which supports the stock price.

  This is a key positive fundamental driver showing Sanofi's growth diversification.

• ▲

  Expanded Regeneron alliance Sanofi will pay $1 billion upfront and up to $7 billion in milestones to co-develop four new antibodies with Regeneron. This broadens Sanofi's pipeline and settles litigation, boosting investor confidence.

  This major partnership expansion is a new positive catalyst for Sanofi's future growth.

• ▼

  Competitive threats to key drugs Novartis's remibrutinib beat Sanofi's Aubagio in MS trials, and AstraZeneca's tozorakimab may reach more COPD patients than Dupixent. These rival drugs could erode Sanofi's sales in important markets.

  These competitive losses directly threaten Sanofi's existing product revenue.

• ◆

  Portfolio restructuring with Cheplapharm Sanofi is handing 20 mature medicines and three plants to Cheplapharm for a 26.4% stake. This simplifies the business but removes steady revenue, with no impact on 2026 guidance.

  This strategic divestment has ambiguous implications for Sanofi's future earnings.

Based on 8 stories →

• ▲

  EU approval of MenQuadfi for infants Sanofi won EU approval to use its MenQuadfi vaccine in infants as young as six weeks, opening a new market. This should boost vaccine sales and strengthen Sanofi's pediatric portfolio, supporting the stock price.

  This is a new regulatory win that directly expands Sanofi's vaccine market and revenue potential.

• ▲

  Novavax partnership advances with milestones Sanofi's partnership with Novavax is progressing, with a Phase 3 COVID/flu combo study planned and milestone payments ahead. Sanofi will lead commercial launches of Nuvaxovid, adding to its vaccine business and future revenue.

  This shows Sanofi's collaboration is moving forward, with potential milestone income and expanded commercial reach.

• ▼

  Permanent halt of infant RSV vaccine trial Sanofi permanently stopped its Phase 3 RSV vaccine trial in infants after an infant death, raising safety and regulatory concerns. This removes a potential future product and may hurt Sanofi's reputation in pediatric vaccines, weighing on the stock.

  This is a major pipeline setback with reputational and regulatory implications that could lower investor confidence.

• ▼

  Competition heats up from AbbVie and Moderna AbbVie is buying Apogee to get a drug that could rival Sanofi's top-selling Dupixent, while Moderna won FDA approval for the first mRNA flu shot, challenging Sanofi's flu vaccine franchise. Both threaten key Sanofi products.

  These are new competitive threats that could pressure Sanofi's sales in two major areas: immunology and flu vaccines.

Based on 6 stories →

• ▲

  Q2 earnings beat and raised 2026 guidance Sanofi reported Q2 sales up 17.8% and raised its 2026 outlook, with Dupixent sales jumping 37.6% to €5.2 billion. This strong performance and confident guidance signal accelerating growth, which should lift investor confidence and support a higher share price.

  This is the most significant new event, directly showing Sanofi's financial health and future prospects.

• ▼

  Amlitelimab development halted for atopic dermatitis Sanofi discontinued amlitelimab for moderate-to-severe atopic dermatitis, a key pipeline candidate, due to insufficient efficacy and safety data. This removes a potential growth driver and may hurt sentiment, as investors had high hopes for the drug in a large market.

  This is a major pipeline setback that could negatively impact future revenue expectations.

• ▲

  Dupixent partner Regeneron beats estimates Regeneron's strong quarterly results, driven by Dupixent sales up 38% to $6 billion, confirm robust demand for Sanofi's top-selling drug. As Sanofi records these sales, the beat reinforces confidence in Dupixent's growth trajectory and Sanofi's earnings power.

  This provides independent validation of Dupixent's blockbuster performance, a key value driver for Sanofi.

• ▲

  Aqemia AI collaboration expands with new target Sanofi expanded its AI-driven drug discovery partnership with Aqemia, nominating a new target and potentially paying up to $140 million in milestones. This strengthens Sanofi's early-stage pipeline and shows commitment to innovative technologies, which could yield future blockbuster drugs.

  This highlights Sanofi's investment in cutting-edge R&D, supporting long-term growth prospects.

Based on 6 stories →

• ▲

  FDA approves Sarclisa Escena on-body injector The FDA approved subcutaneous Sarclisa Escena for all multiple myeloma uses, the first anticancer treatment given via on-body injector. It cuts treatment time and infusion reactions, which can lift sales and strengthen Sanofi's cancer franchise.

  This is a new regulatory approval that expands a key product's use and could drive future revenue.

• ▲

  Nexviazyme hits all goals in infant Pompe disease trial Sanofi's Nexviazyme met all endpoints in a phase 3 study for infants with infantile-onset Pompe disease, supporting a US label extension filing later in 2026. Success in a rare disease with few options adds a new growth driver.

  Positive late-stage trial data for an existing drug opens a new patient population and revenue stream.

• ▲

  WAYRILZ positioned in fast-growing AIHA market A market report projects 14.4% annual growth for warm autoimmune hemolytic anemia treatments through 2036, with no approved therapies yet. Sanofi's WAYRILZ is a key late-stage candidate, giving it a large untapped opportunity if approved.

  Highlights a new market opportunity for a Sanofi pipeline drug, supporting long-term growth prospects.

• ▼

  UBS cautious on Sanofi within favored pharma sector UBS likes European pharma as a safer bet than AI but is more cautious on Sanofi, preferring AstraZeneca and Roche. This relative caution may steer some investor money away from Sanofi shares, limiting upside versus peers.

  Analyst preference can influence capital flows and relative stock performance.

Based on 6 stories →

• ▲

  Dupixent sales surge 30.8% to €4.17B Dupixent sales jumped 30.8% to €4.17 billion in Q1 2026, driven by new approvals including COPD. Management targets €22 billion by 2030. This strong growth supports Sanofi's revenue and profit outlook, pushing the stock up.

  Dupixent is Sanofi's biggest growth driver, and its sales performance directly impacts earnings and investor confidence.

• ▲

  Multiple new drug approvals in Japan and EU Sanofi received approvals for Sarclisa SC and Wayrilz in Japan, and Cenrifki in the EU. These expand its specialty care portfolio into new markets and indications, offering new revenue streams and boosting long-term growth prospects.

  New approvals open additional revenue sources and demonstrate pipeline strength, which can lift the stock.

• ▼

  EU antitrust probe into flu vaccine marketing The EU opened an antitrust investigation into Sanofi over alleged disparagement of a rival flu vaccine. If confirmed, Sanofi could face a fine for abuse of dominance. This creates legal and financial uncertainty, weighing on the stock.

  Regulatory investigations can lead to fines and reputational damage, directly affecting investor sentiment and potential costs.

• ▼

  AbbVie acquires Apogee to compete with Dupixent AbbVie is buying Apogee Therapeutics for $10.9 billion, gaining zumilokibart, a potential competitor to Dupixent with less frequent dosing. This intensifies competition in inflammatory diseases, threatening future Dupixent sales and market share.

  Competitive threats to Sanofi's top-selling drug can pressure future revenue and stock valuation.

Based on 10 stories →

• ▲

  Tulisokibart hits Phase 2b goal in skin disease Merck's anti-TL1A drug tulisokibart met its main goal in a mid-stage hidradenitis suppurativa trial, with 72% of high-dose patients responding versus 35% on placebo. This is the first positive Phase 2 result for this drug class in dermatology, opening a new growth area beyond cancer and supporting the stock.

  New clinical win shows pipeline diversification beyond Keytruda, a key positive for future revenue.

• ▲

  Merck licenses KRAS cancer drug for up to $2.13B Merck paid $400 million upfront for global rights to SciBrunch's SPR2015, a preclinical KRAS G12D inhibitor for pancreatic, colorectal and lung cancers, with total deal value up to $2.13 billion. This adds a promising early cancer asset, though it will cause a $0.13 per share charge in Q3 results.

  New licensing deal expands oncology pipeline, a strategic positive despite a small near-term earnings hit.

• ▲

  Oral drug delivery tech enters human testing MSD began a Phase 1 trial of a proprietary drug using Cyprumed's oral delivery technology, triggering a milestone payment. If successful, this could let Merck turn injectable peptides into pills, a big manufacturing and patient convenience advantage that supports the pipeline.

  New technology milestone that could improve drug delivery and extend product lifecycles.

• ▼

  AstraZeneca's $2B bet on Keytruda rival Summit AstraZeneca will invest $2 billion in Summit Therapeutics and lead trials combining Summit's ivonescimab with AstraZeneca's cancer drugs. Ivonescimab has already beaten Keytruda in lung cancer survival, so this deepens the competitive threat to Merck's biggest franchise ahead of its 2028 patent expiry.

  New competitive escalation directly pressures Keytruda, Merck's largest revenue source.

Based on 6 stories →

• ▲

  Multiple FDA and global label expansions for Keytruda, Winrevair, and Welireg Merck won FDA label updates for Winrevair (adding Phase 3 HYPERION data showing 76% reduction in clinical worsening) and Welireg plus Lenvima for advanced kidney cancer, plus Japanese approval for subcutaneous Keytruda across all indications. These expand approved uses and strengthen revenue durability.

  These regulatory wins directly broaden Merck's product labels and market reach, supporting future sales growth.

• ▲

  Pipeline advances in remigromig and Keytruda combinations Merck's remigromig met its primary goal in a Phase IIb/III diabetic macular edema study, a first-in-class eye drug. Also, Inhibrx's INBRX-106 combined with Keytruda nearly doubled response rates in head and neck cancer, reinforcing Keytruda's backbone role.

  These pipeline successes show Merck's R&D engine is producing new growth drivers beyond current drugs.

• ▼

  Keytruda faces competitive and regulatory setbacks Summit's ivonescimab cut death risk 27% versus Keytruda in lung cancer, a direct threat. Separately, Merck and Daiichi Sankyo withdrew a US application for ifinatamab deruxtecan after FDA said data didn't support accelerated approval, delaying a pipeline candidate.

  These events pressure Keytruda's dominance and remove a near-term pipeline catalyst, weighing on sentiment.

• ▲

  Measles outbreak boosts demand for Merck's MMR vaccine A US measles outbreak with 3,471 cases and 95% in unvaccinated people increases demand for Merck's MMR vaccine. This provides a modest but steady revenue lift from an existing product.

  Rising disease incidence directly drives higher vaccine sales for Merck.

Based on 9 stories →

• ▲

  Pipeline triples to offset Keytruda patent cliff Merck's phase III pipeline has nearly tripled since 2021, with 20 new drug launches expected by 2030 to replace Keytruda's 2028 patent loss. Acquisitions like Verona, Cidara and Terns add new growth. This reassures investors that the coming revenue drop may be a shallow dip, supporting the stock.

  This is the central strategic force behind Merck's valuation and directly addresses its biggest risk.

• ▲

  Q2 sales beat, guidance raised, Keytruda strong Merck reported Q2 sales of $16.6 billion, with Keytruda franchise at $8.4 billion, and raised full-year 2026 guidance to $66.3–$67.3 billion. Winrevair jumped 75% to $588 million. Solid results and confident outlook support the stock, though a $5.7 billion acquisition charge caused a reported loss.

  Earnings and guidance are key fundamental drivers that show current business strength and future expectations.

• ▼

  Keytruda rival shows survival advantage Summit's ivonescimab cut death risk by 27% versus Keytruda in a lung cancer trial, with an 8.2-month survival advantage. This is a direct competitive threat to Merck's biggest drug, pressuring the stock as it raises doubts about Keytruda's long-term dominance.

  This is a major competitive development that could erode Keytruda's franchise, a core part of Merck's value.

• ▲

  EU approval advances Keytruda bladder cancer combo EU regulators gave a positive opinion for Keytruda plus Padcev in resectable muscle-invasive bladder cancer, with final approval expected by Q4 2026. This expands Keytruda's use into earlier-stage disease, adding a new revenue stream and strengthening the franchise.

  Regulatory progress opens a new market for Keytruda, directly supporting future sales growth.

Based on 9 stories →

• ▲

  mRNA cancer vaccine success drives healthcare rally Merck and Moderna's personalized mRNA cancer vaccine met its main Phase 3 goal in melanoma, cutting recurrence when added to Keytruda. The news sparked a broad healthcare rally, with Merck up 12% in a day and the sector posting its best week since June. This opens a major new growth path for Merck's oncology business.

  This is the biggest new event of the period, directly boosting Merck's growth outlook and stock.

• ▲

  Analysts see multi-billion sales potential for vaccine Barclays estimates the vaccine could generate up to $3 billion in annual melanoma sales by 2035, and the global melanoma drug market is projected to grow from $5.8 billion in 2024 to $10.3 billion by 2030. This supports expectations of a meaningful new revenue stream for Merck.

  It quantifies the financial upside of the vaccine, which is key to why Merck's stock is moving.

• ▲

  LIPFENDRA approval opens high-growth cholesterol market Merck's LIPFENDRA, the first oral PCSK9 cholesterol drug, has been approved by the FDA, driving the PCSK9 inhibitor market into a high-growth phase. This adds a new cardiometabolic pillar to Merck's business, diversifying revenue beyond Keytruda and supporting long-term growth.

  It shows a new approved product expanding Merck's revenue base, which investors view positively.

• ▼

  Keytruda biosimilar and rival lung cancer threat Cipla's US unit secured exclusive rights to commercialize a proposed pembrolizumab biosimilar ahead of Keytruda's 2028 patent expiry. Separately, Summit Therapeutics' ivonescimab showed superior overall survival versus Keytruda in a lung cancer trial. These developments increase competition and pressure Merck's biggest franchise.

  It is the main counterweight to the positive news, highlighting risks to Merck's key revenue source.

Based on 7 stories →

• ▲

  First Phase 3 win for mRNA cancer vaccine with Moderna Merck and Moderna's personalized mRNA cancer vaccine met its main goal in a Phase 3 melanoma trial, cutting recurrence when added to Keytruda. This is the first late-stage win for an mRNA cancer therapy, opening a new growth path for Merck's oncology business.

  This is the biggest new catalyst driving MRK's stock to a 52-week high.

• ▲

  Analysts see multi-billion sales potential for the vaccine Bank of America raised its peak sales estimate for the vaccine to $54 billion and upgraded Moderna, noting Merck shares 50% of the economics. Barclays sees about $3 billion in annual melanoma sales by 2035. This supports expectations of a meaningful new revenue stream.

  Analyst upgrades and sales estimates directly influence investor expectations and stock price.

• ▲

  Broader pipeline expansion across cancers The companies are testing the vaccine-Keytruda combo in nine Phase 2 and Phase 3 trials covering lung, bladder, kidney, pancreatic and gastric cancers. Success in more tumor types would further extend Keytruda's franchise and diversify Merck's revenue beyond its current uses.

  Pipeline expansion reduces reliance on Keytruda and supports long-term growth narrative.

• ◆

  Moderna's sharp reversal shows volatility Moderna shares plunged 20% the day after a 177% surge, a reminder that early-stage biotech wins can be volatile. For Merck, the milestone is real but the vaccine is not approved yet, and near-term revenue depends on regulatory review and further trial results.

  This counterweight reminds investors that the vaccine is not yet approved and near-term revenue is uncertain.

Based on 21 stories →

• ▲

  Phase 3 mRNA cancer vaccine success Merck and Moderna's personalized mRNA cancer vaccine met its main goal in a Phase 3 melanoma trial, cutting recurrence when added to Keytruda. This is the first late-stage win for an mRNA cancer therapy, opening a new growth path for Merck's oncology business.

  This is the single new event that drove Merck's stock up over 11% and sets up a potential new product.

• ▲

  Analysts see multi-billion sales potential Bank of America raised its peak sales estimate for the vaccine to $54 billion and upgraded Moderna, noting Merck shares 50% of the economics. Barclays sees about $3 billion in annual melanoma sales by 2035. This supports expectations of a meaningful new revenue stream.

  Analyst estimates quantify the financial upside for Merck, reinforcing the positive stock reaction.

• ▲

  Broader pipeline expansion across cancers The companies are testing the vaccine-Keytruda combo in nine Phase 2 and Phase 3 trials covering lung, bladder, kidney, pancreatic and gastric cancers. Success in more tumor types would further extend Keytruda's franchise and diversify Merck's revenue beyond its current uses.

  It shows the win is not a one-off but part of a larger strategy that could drive long-term growth.

• ◆

  Moderna's sharp reversal shows volatility Moderna shares plunged 20% the day after a 177% surge, a reminder that early-stage biotech wins can be volatile. For Merck, the milestone is real but the vaccine is not approved yet, and near-term revenue depends on regulatory review and further trial results.

  It provides a fair counterweight: the excitement is justified but not without risk, and Merck's own stock move was more measured.

Based on 18 stories →

• ▲

  Q2 Beat and Raised 2026 Guidance Merck reported Q2 revenue of $16.61 billion, up 5% and above estimates, with Keytruda sales of $8.37 billion. Management raised full-year 2026 revenue guidance to $66.3–$67.3 billion. This directly boosts investor confidence and supports a higher stock price.

  This is the period's biggest new financial catalyst, showing stronger-than-expected results and a brighter outlook.

• ▲

  Keytruda Label Expansions in Canada and EU Diagnostic Health Canada approved Keytruda with enfortumab vedotin for bladder cancer, and Agilent's EU companion diagnostic helps identify more patients for Keytruda. These expand Keytruda's use into new patient groups, supporting future sales growth as Merck faces eventual patent expiration.

  New approvals and diagnostic tools widen Keytruda's market, a key growth driver for Merck.

• ▲

  New Drug Approvals and Pipeline Progress FDA approved LIPFENDRA, the first oral PCSK9 cholesterol drug, adding a new cardiometabolic pillar. Merck also advanced HIV prevention access and reported positive Phase 3 results for a once-weekly HIV regimen. These diversify revenue beyond Keytruda and support long-term growth.

  These new products and pipeline wins show Merck building future revenue streams, reducing reliance on Keytruda.

• ◆

  Acquisition Charges Weigh on Reported Earnings Merck's $11.3 billion Bio-Techne and $9 billion Cidara acquisitions, plus a $5.7 billion Terns charge, caused a reported quarterly loss. While these deals aim to replenish the pipeline, the large cash outlays and charges pressure near-term reported profits and could weigh on sentiment.

  This is the main counterweight: big spending and accounting losses offset strong operational results.

Based on 10 stories →

• ▲

  Keytruda Endometrial Cancer Win Merck's Keytruda met its main goal in a Phase 3 endometrial cancer trial, showing better progression-free survival than chemotherapy. This expands Keytruda's use into a new cancer type, supporting future sales as the company faces patent expiration.

  New clinical win expands Keytruda's label and supports long-term revenue.

• ▲

  FDA Approves First Oral PCSK9 Inhibitor LIPFENDRA Merck won FDA approval for LIPFENDRA, the first once-daily oral PCSK9 inhibitor for high cholesterol. It cut LDL-C by up to 59% in trials and offers an easier option than injectables, opening a large new market for Merck.

  New product approval opens a major new revenue stream beyond oncology.

• ▲

  HIV Pipeline Advances with Gilead and Access Plan Merck and Gilead reported positive Phase 3 results for a once-weekly oral HIV regimen, and Merck unveiled an early access plan for its once-monthly HIV prevention pill in 129 low- and middle-income countries. These moves strengthen Merck's HIV franchise and future demand.

  New HIV data and access strategy expand Merck's pipeline and global reach.

• ▼

  Generic Janumet XR Launch Erodes Sales Par Health launched the first generic version of Merck's Janumet XR diabetes drug in the U.S. This will cut into Merck's sales of the branded product, which had about $270 million in annual U.S. revenue, as cheaper copies take market share.

  New generic competition directly pressures an existing Merck product's revenue.

Based on 10 stories →

• ▼

  U.S. House Committee Probes Merck's China Clinical Trials A House committee is investigating Merck's clinical trials at Chinese military sites and in Xinjiang, raising concerns about ethics, data security, and intellectual property. This regulatory and headline risk could weigh on the stock, especially if it leads to restrictions or reputational damage.

  This is a new negative regulatory event that introduces uncertainty and potential downside for MRK.

• ▼

  COVID-19 EUA Termination Hits Merck's Lagrevio The U.S. government ended emergency use authorizations for COVID-19 drugs, including Merck's Lagrevio. This removes a revenue stream and could lower future sales expectations, though the impact may be limited if COVID-19 remains endemic and traditional approvals are pursued.

  This is a new regulatory change that directly reduces Merck's COVID-19 product sales.

• ▲

  Keytruda Wins New U.S. and EU Approvals in Breast and Bladder Cancer Merck received FDA and EU approvals for Keytruda-based regimens in triple-negative breast cancer and muscle-invasive bladder cancer, including a subcutaneous form. These expand Keytruda's label into earlier and tougher tumors, supporting sales growth as the company prepares for patent expiration.

  These new approvals broaden Keytruda's market and reinforce Merck's oncology strategy, a key positive driver.

• ▲

  Tulisokibart Phase 3 Success Strengthens Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met its main goal in a Phase 3 ulcerative colitis trial. This is a first for this drug class and helps diversify Merck beyond oncology, offsetting future Keytruda competition and supporting long-term growth.

  This pipeline win is a new positive development that boosts Merck's diversification efforts.

Based on 8 stories →

• ▲

  Tulisokibart Phase 3 Win Boosts Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met the main goal in a Phase 3 ulcerative colitis trial, a first for this type of drug. This strengthens Merck's pipeline beyond cancer and helps offset future Keytruda competition, supporting the stock.

  This is a new positive pipeline event that directly addresses Merck's post-Keytruda growth story.

• ▲

  FDA and EU Approvals Expand Keytruda, Welireg, and Capvaxive Labels Merck won new approvals for Keytruda+Welireg in kidney cancer, Capvaxive in children, and Keytruda+Padcev in bladder cancer in the EU. These expand patient populations and should lift sales of these drugs.

  These are new regulatory wins that broaden Merck's marketed products and drive revenue growth.

• ▼

  Proposed CMS Rule to Make Medicare Drug Price Negotiations Permanent A proposed CMS rule would make Medicare drug price negotiations permanent, directly pressuring Merck's pricing. This regulatory overhang could cap future revenue growth and weighs on the stock.

  This is a new regulatory threat that could negatively impact Merck's pricing and profits.

• ▲

  Abu Dhabi Logistics Hub to Expand Regional Distribution Merck (MSD) is partnering with Abu Dhabi to explore a regional logistics hub, which could improve supply chain resilience and access to its therapies in the Middle East. This supports long-term demand.

  This new partnership could enhance Merck's distribution and market access in a growing region.

Based on 15 stories →